Aliri

Executive Summary

Aliri Bioanalysis is a well-established French contract research organization (CRO) founded in 2011 that provides advanced bioanalytical and spatial biology services to pharmaceutical and biotech clients. Headquartered in Nantes, France, the company specializes in pharmacokinetics, biomarker analysis, and tissue-based spatial multi-omics, offering method development, validation, and sample analysis under GLP and GCP standards. With a decade of experience and support across drug discovery to clinical development, Aliri has positioned itself as a reliable partner for complex bioanalytical needs, particularly in the growing spatial biology segment. The company's current 'Phase 3' status likely reflects its maturity and ongoing support for late-stage clinical trials, although it remains a private entity with undisclosed funding and valuation. Aliri's focus on high-quality, regulatory-compliant services positions it well in the competitive CRO landscape, especially as demand for spatial omics and biomarker analysis increases. The company's strong reputation and niche expertise suggest a steady growth trajectory, though its private nature limits public visibility.

Upcoming Catalysts (preview)

• Q3 2026Launch of New Spatial Multi-Omics Platform65% success
• TBDMajor Partnership with a Top-20 Pharma Company50% success
• Q4 2026Expansion of GLP-Certified Laboratory Facilities70% success